- Conditions
- Substance Use
- Interventions
- Standard Screening, Standard Psychoeducation, Standard Brief Negotiated Interview (BNI), Standard Referral to Treatment (RT), Family Screening, Family Psychoeducation, Family Brief Negotiated Interview (BNI), Family Facilitated Conversation (FC) & Referral to Treatment (RT)
- Behavioral
- Lead sponsor
- The National Center on Addiction and Substance Abuse at Columbia University
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 2,300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 44
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- COVID-19
- Interventions
- ALG-097558, Dabigatran, Itraconazole, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Bone Marrow Failure, Hemoglobinopathies, Primary Immune Deficiency (PID), Autoimmune Cytopenia, Immune Dysregulation, Hemophagocytic Lymphohistiocytosis (HLH), Non Malignant Disorders
- Interventions
- ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs
- Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 6 Months to 50 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- GERD
- Interventions
- Esomeprazole
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Anaheim, California • Orange, California + 16 more
- Conditions
- Adolescent Drinking, Adolescent Substance Use, Risk Behavior, Health
- Interventions
- Indicated Prevention, Clinical Staff, Selective Prevention, Expanded Paraprofessional Workforce
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 19 Years
- Enrollment
- 21,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer Disease
- Interventions
- Escitalopram Pill, Venlafaxine Pill, Placebo Oral Tablet
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obesity, Weight Gain, Eating Disorders
- Interventions
- Healthy Weight, Project Health, Placebo Control
- Behavioral
- Lead sponsor
- Oregon Research Institute
- Other
- Eligibility
- 17 Years to 23 Years
- Enrollment
- 364 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2018
- U.S. locations
- 4
- States / cities
- Corvallis, Oregon • Eugene, Oregon • Austin, Texas
- Conditions
- NSAIDs, Upper GI Symptoms
- Interventions
- Esomeprazole
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 31
- States / cities
- Tallassee, Alabama • Phoenix, Arizona • Garden Grove, California + 28 more
- Conditions
- Hypertension, Diabetes, Cardiovascular Disease
- Interventions
- Carvedilol, Spironolactone, Usual care
- Drug · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Anemia
- Interventions
- Daily iron supplements of 65 mg a day for 3 months, Universal anemia screening and treatment, Selective anemia screening and treatment
- Behavioral
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 13 Years and older · Female only
- Enrollment
- 959 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Hattiesburg, Mississippi
- Conditions
- Ductal Carcinoma in Situ
- Interventions
- Tamoxifen, Exemestane, Letrozole, Anastrazole, Testosterone + Anastrazole, Elacestrant, Z-endoxifen
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 28
- States / cities
- Berkeley, California • Duarte, California • Irvine, California + 21 more
- Conditions
- Substance Abuse, Mental Health
- Interventions
- Positive Behavior Supports in Middle Schools
- Behavioral
- Lead sponsor
- University of Oregon
- Other
- Eligibility
- 11 Years to 15 Years
- Enrollment
- 13,498 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Eugene, Oregon
- Conditions
- Kidney Transplantation, Renal Transplant Recipients
- Interventions
- Lulizumab, Tacrolimus, Thymoglobulin®, Methylprednisolone, Mycophenolate Mofetil, Prednisone
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Nicotine Dependence
- Interventions
- GSK598809, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- Ondansetron, Palonosetron
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Laguna Hills, California • San Francisco, California + 5 more
- Conditions
- Graft Vs Host Disease
- Interventions
- Cyclophosphamide, Abatacept, Tacrolimus
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Head and Neck Cancer, Precancerous Condition
- Interventions
- celecoxib
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Refractory Childhood Acute Lymphoblastic Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Peripheral Blood Stem Cell Transplantation, T Cell-Depleted Hematopoietic Stem Cell Transplantation, Tacrolimus, Thiotepa, Total-Body Irradiation
- Procedure · Drug · Other + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Allogeneic Hematopoietic Stem Cell Transplant Recipient, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Donor, Lymphoblastic Lymphoma, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Thiotepa, Total-Body Irradiation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2025
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Seattle, Washington
- Conditions
- Graft Versus Host Disease, Graft Vs Host Disease, Hematologic Malignancy
- Interventions
- Belumosudil
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- HIV Infections
- Interventions
- Maximal Control, Instrumental and Empowering, Minimal Control, Instrumental, Empowering
- Behavioral
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 722 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Insulin Sensitivity, Obesity
- Interventions
- Cold exposure, Cold exposure plus propranolol, Thermoneutral Conditions, Cold water consumption, Tepid water consumption, Exercise, Meal consumption
- Other
- Lead sponsor
- Rutgers University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Healthy
- Interventions
- Atenolol 50 MG, Placebo
- Drug
- Lead sponsor
- Sundeep Khosla, M.D.
- Other
- Eligibility
- 50 Years to 75 Years · Female only
- Enrollment
- 420 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- Scarborough, Maine • Rochester, Minnesota • New York, New York
- Conditions
- Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia, BRCA2 Mutation, CHEK2 Gene Mutation, Ataxia Telangiectasia Mutated Gene Mutation
- Interventions
- Exemestane, Tamoxifen
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Female only
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts